251 related articles for article (PubMed ID: 17693574)
21. Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains.
Brügmann A; Eld M; Lelkaitis G; Nielsen S; Grunkin M; Hansen JD; Foged NT; Vyberg M
Breast Cancer Res Treat; 2012 Feb; 132(1):41-9. PubMed ID: 21512768
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the HER2 amplification status in oesophageal adenocarcinoma by conventional and automated FISH: a tissue microarray study.
Prins MJ; Ruurda JP; van Diest PJ; van Hillegersberg R; ten Kate FJ
J Clin Pathol; 2014 Jan; 67(1):26-32. PubMed ID: 24043715
[TBL] [Abstract][Full Text] [Related]
23. Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer.
Skaland I; Øvestad I; Janssen EA; Klos J; Kjellevold KH; Helliesen T; Baak JP
J Clin Pathol; 2008 Jan; 61(1):68-71. PubMed ID: 17412872
[TBL] [Abstract][Full Text] [Related]
24. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
Laakso M; Tanner M; Isola J
J Pathol; 2006 Sep; 210(1):3-9. PubMed ID: 16823892
[TBL] [Abstract][Full Text] [Related]
25. Numeric aberrations of HER-2 and chromosome 17 detected by fluorescence in situ hybridization in urine-exfoliated cells from patients with urothelial carcinoma.
Inoue T; Sato K; Tsuchiya N; Matsuura S; Iinuma M; Habuchi T; Kato T
Urology; 2004 Sep; 64(3):617-21. PubMed ID: 15351620
[TBL] [Abstract][Full Text] [Related]
26. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer.
Viale G
J Pathol; 2009 Sep; 219(1):1-2. PubMed ID: 19670216
[TBL] [Abstract][Full Text] [Related]
27. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
Jiang H; Bai X; Zhao T; Zhang C; Zhang X
Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
[TBL] [Abstract][Full Text] [Related]
28. Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.
Tafe LJ; Allen SF; Steinmetz HB; Dokus BA; Cook LJ; Marotti JD; Tsongalis GJ
Exp Mol Pathol; 2014 Aug; 97(1):116-9. PubMed ID: 24927872
[TBL] [Abstract][Full Text] [Related]
29. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
Torrisi R; Rotmensz N; Bagnardi V; Viale G; Curto BD; Dell'orto P; Veronesi P; Luini A; D'Alessandro C; Cardillo A; Goldhirsch A; Colleoni M
Eur J Cancer; 2007 Nov; 43(16):2339-44. PubMed ID: 17855075
[TBL] [Abstract][Full Text] [Related]
30. FISH and chips: automation of fluorescent dot counting in interphase cell nuclei.
Netten H; Young IT; van Vliet LJ; Tanke HJ; Vroljik H; Sloos WC
Cytometry; 1997 May; 28(1):1-10. PubMed ID: 9136750
[TBL] [Abstract][Full Text] [Related]
31. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience.
Tubbs RR; Hicks DG; Cook J; Downs-Kelly E; Pettay J; Hartke MB; Hood L; Neelon R; Myles J; Budd GT; Moore HC; Andresen S; Crowe JP
Diagn Mol Pathol; 2007 Dec; 16(4):207-10. PubMed ID: 18043283
[TBL] [Abstract][Full Text] [Related]
32. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
[TBL] [Abstract][Full Text] [Related]
33. Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancer.
Egervari K; Kosa C; Szollosi Z
Pathol Res Pract; 2011 Aug; 207(8):468-71. PubMed ID: 21741182
[TBL] [Abstract][Full Text] [Related]
34. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.
Monego G; Arena V; Maggiano N; Costarelli L; Crescenzi A; Zelano G; Amini M; Capelli A; Carbone A
Scand J Clin Lab Invest; 2007; 67(4):402-12. PubMed ID: 17558895
[TBL] [Abstract][Full Text] [Related]
35. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues.
Rauser S; Weis R; Braselmann H; Feith M; Stein HJ; Langer R; Hutzler P; Hausmann M; Lassmann S; Siewert JR; Höfler H; Werner M; Walch A
Clin Cancer Res; 2007 Sep; 13(17):5115-23. PubMed ID: 17785566
[TBL] [Abstract][Full Text] [Related]
36. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
37. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
[TBL] [Abstract][Full Text] [Related]
38. Smart 3D-FISH: automation of distance analysis in nuclei of interphase cells by image processing.
Gué M; Messaoudi C; Sun JS; Boudier T
Cytometry A; 2005 Sep; 67(1):18-26. PubMed ID: 16082715
[TBL] [Abstract][Full Text] [Related]
39. Automated quantification of FISH signals in urinary cells enables the assessment of chromosomal aberration patterns characteristic for bladder cancer.
Köhler CU; Martin L; Bonberg N; Behrens T; Deix T; Braun K; Noldus J; Jöckel KH; Erbel R; Sommerer F; Tannapfel A; Harth V; Käfferlein HU; Brüning T
Biochem Biophys Res Commun; 2014 Jun; 448(4):467-72. PubMed ID: 24802410
[TBL] [Abstract][Full Text] [Related]
40. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up.
Jensen KC; Turbin DA; Leung S; Miller MA; Johnson K; Norris B; Hastie T; McKinney S; Nielsen TO; Huntsman DG; Gilks CB; West RB
Breast Cancer Res Treat; 2008 Dec; 112(3):453-9. PubMed ID: 18193353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
